Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DKN-01 + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Leap Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of DKN-01 (sirexatamab), lenalidomide, and dexamethasone, investigated primarily for treatment of relapsed or refractory multiple myeloma. DKN-01 is a humanized IgG4 monoclonal antibody that binds and neutralizes Dickkopf-1 (DKK1), a secreted inhibitor of Wnt signaling associated with tumor growth, immune suppression, and poor prognosis. Lenalidomide is an immunomodulatory small molecule with antineoplastic, antiangiogenic, and pro-immune effects, while dexamethasone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. The combination is designed to suppress tumor proliferation, stimulate immune response, and inhibit tumor-induced immune evasion and bone disease in multiple myeloma.
- Other names
- sirexatamablenalidomidedexamethasone
02
Targets
DKK1 (Dickkopf-related protein 1)GR (Glucocorticoid receptor)CRBN (Cereblon)
Beyond the preview
Go deeper on DKN-01 + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DKN-01 + lenalidomide + dexamethasone.